These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35120852)

  • 1. The Effect of Fedratinib, A Selective Inhibitor of Janus Kinase 2, on Weight and Metabolic Parameters in Patients with Intermediate- or High-risk Myelofibrosis.
    Tremblay D; Cavalli L; Sy O; Rose S; Mascarenhas J
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e463-e466. PubMed ID: 35120852
    [No Abstract]   [Full Text] [Related]  

  • 2. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
    Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
    Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts.
    Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Passamonti F; Zweegman S; Talpaz M; Verstovsek S; Rose S; Zhang J; Sy O; Mesa RA
    Br J Haematol; 2022 Jul; 198(2):317-327. PubMed ID: 35476316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fedratinib: First Approval.
    Blair HA
    Drugs; 2019 Oct; 79(15):1719-1725. PubMed ID: 31571162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure.
    Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Jourdan E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Verstovsek S; Rose S; Shen J; Berry T; Brownstein C; Mesa RA
    Am J Hematol; 2020 Jun; 95(6):594-603. PubMed ID: 32129512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis.
    Pardanani A; Tefferi A; Masszi T; Mishchenko E; Drummond M; Jourdan E; Vannucchi A; Jurgutis M; Ribrag V; Rambaldi A; Koh LP; Rose S; Zhang J; Harrison C
    Br J Haematol; 2021 Oct; 195(2):244-248. PubMed ID: 34331348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fedratinib hydrochloride to treat intermediate-2 or high-risk primary or secondary myelofibrosis.
    Schiffer M; Kowalski A; Zhao J; Bewersdorf JP; Lewis RS; Zeidan AM
    Drugs Today (Barc); 2020 Dec; 56(12):755-768. PubMed ID: 33332482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fedratinib: a pharmacotherapeutic option for JAK-inhibitor naïve and exposed patients with myelofibrosis.
    England JT; Gupta V
    Expert Opin Pharmacother; 2022 Oct; 23(15):1677-1686. PubMed ID: 36252265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib.
    Saha C; Harrison C
    Expert Rev Hematol; 2022 Jul; 15(7):583-595. PubMed ID: 35787092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of myelofibrosis after ruxolitinib failure.
    Harrison CN; Schaap N; Mesa RA
    Ann Hematol; 2020 Jun; 99(6):1177-1191. PubMed ID: 32198525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Clinical Investigations in Myelofibrosis.
    Venugopal S; Mascarenhas J
    Hematol Oncol Clin North Am; 2021 Apr; 35(2):353-373. PubMed ID: 33641874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.
    Pardanani A; Harrison C; Cortes JE; Cervantes F; Mesa RA; Milligan D; Masszi T; Mishchenko E; Jourdan E; Vannucchi AM; Drummond MW; Jurgutis M; Kuliczkowski K; Gheorghita E; Passamonti F; Neumann F; Patki A; Gao G; Tefferi A
    JAMA Oncol; 2015 Aug; 1(5):643-51. PubMed ID: 26181658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.
    Ostojic A; Vrhovac R; Verstovsek S
    Future Oncol; 2011 Sep; 7(9):1035-43. PubMed ID: 21919691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and future role of fedratinib in the treatment of myelofibrosis.
    Ragheb M; Harrison CN; McLornan DP
    Future Oncol; 2020 Feb; 16(6):175-186. PubMed ID: 31971457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fedratinib in myelofibrosis.
    Mullally A; Hood J; Harrison C; Mesa R
    Blood Adv; 2020 Apr; 4(8):1792-1800. PubMed ID: 32343799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia.
    Ogasawara K; Zhou S; Krishna G; Palmisano M; Li Y
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):891-898. PubMed ID: 31444617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.
    Singer JW; Al-Fayoumi S; Taylor J; Velichko S; O'Mahony A
    PLoS One; 2019; 14(9):e0222944. PubMed ID: 31560729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
    Talpaz M; Kiladjian JJ
    Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
    Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
    N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib.
    Wu F; Krishna G; Surapaneni S
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):461-473. PubMed ID: 32886148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.